Page 94 - JSOM Winter 2025
P. 94

Weighted   score  37  46  40       46        35             42





                            Stewardship  [3]  No concerns    (1)  Moderate   concerns    (3)  Minor concerns    (2)  Minor concerns    (2)  Minor concerns    (2)  Moderate   concerns    (3)




                          MDRO (PsA   or MRSA)    [0]  Not reliable    (4)  Yes, PsA    (1)  Not reliable    (4)  Not reliable    (4)  Not reliable    (4)  Not reliable    (4)





                        Antimicrobial Coverage  B. fragilis  Clostridia  [0]  [1]  Not  Not reliable    reliable    (4)  (4)  Not  Not reliable    reliable    (4)  (4)  Growing   Yes    resistance    (1)  (3)  Alt.    Yes    (2)  (1)  Not   Alt.    reliable    (2)  (4)  Yes    Yes    (1)  (1)









                            MSSA  [3]   Yes    (1)  Yes    (1)  Alt.    (2)  Alt.    (2)  Yes    (1)  Yes    (1)

                          Group A   Strep    [4]   Yes    (1)  Yes    (1)  Yes    (1)  Yes    (1)  Yes    (1)  Yes    (1)




                          Clinical   experience   [2]   Combat   trauma    (1)  Combat   trauma    (1)  Combat   trauma    (1)  Combat   trauma    (1)  Combat   trauma    (1)  Combat   trauma    (1) Note “[x]” in column headers refers to weight of that category in calculating the final Weighted Score; “(x)” within the body of the table refers to the category’s score based on Table 2. Lower weighted
                     TABLE 4  Characterization of Parenteral Antimicrobial Agents for Point-of-Injury Administration in TCCC





                          Drug  interactions  [1]   None    (1)  None    (1)  None    (1)  None    (1)  Precipitates  with calcium  co-administration     (3)   Not clinically   significant      (2)



                            Half-life  [3]   2 h    (3)  2 h    (3)  3–4.5 h    (2)  1 h    (4)  5–9 h    (1)  4 h    (1)




                          Adverse  events  [2]   Minor   reactions   <10% of   population    (1)  Minor   reactions   <10% of   population    (1)  Minor   reactions   <10% of   population    (1)  Minor   reactions   <10% of   population    (1)  Minor local   reactions    (skin tightness   / induration)  <10% of   population   via IM admin     (1)  Minor    (i.e. diarrhea)   <10% of   population    (1)




                          Route  (IV/IM)  [2]  Both    (1)  Both    (1)  Both    (1)  Both    (1)  Both    (1)  Both    (1)


                          Infusion  time  [2]  IV push   over    3–5 min    (1)  IV push   over    2–5 min    (1)  IV push   over    3–5 min    (1)  IV push   over    3–5 min    (1)  IV push   over 5 min    (1)  IV push   over 5 min    (1)



                            Mixture  [2]  2g vial   recon with   5mL SWFI    (2)  2g vial   recon with   10mL   SWFI, NS,   D5W    (3)  2g vial   recon with   10mL   SWFI, NS,   D5W    (3)  2g vial   recon with   10mL   SWFI, NS,   D5W    (3)  2g vial   recon with   7mL SWFI,   NS, D5W    (2)  1g vial   recon with   NS or SWFI     (4)



                            $/dose  [1]   1.50    (1)  11.00    (2)  26.60    (2)  14.36    (2)  11.40    (2)  165.00     (4)  scores are considered more favorable.


                              Antibiotic  Cefazolin  Cefepime  Cefotetan  Cefoxitin  Ceftriaxone  Ertapenem




          92  |  JSOM   Volume 25, Edition 4 / Winter 2025
   89   90   91   92   93   94   95   96   97   98   99